Madrigal adds J&J R&D executive John C. Reed to board of directors

Madrigal Pharmaceuticals announced on August 12, 2026 that it had appointed John C. Reed, M.D., Ph.D. to its Board of Directors. The board acted on August 11, 2026, growing its membership from eight to nine directors, with the Nominating and Governance Committee recommending Reed to fill the new seat effective that day.¹ Reed will hold a Class II director position with a term running until the 2027 annual stockholders meeting or until a successor is named.¹ He has also been placed on the Board's Science and Technology Committee.¹

Reed's current role is at Johnson & Johnson, where he serves as Executive Vice President, Innovative Medicine, Research & Development and sits on J&J's Executive Committee, overseeing R&D work spanning oncology, immunology, neuroscience and other high-need therapeutic areas.¹ Before joining J&J in April 2023, he held executive committee roles at Sanofi and Roche, and earlier led Sanford-Burnham Medical Research Institute as President and CEO, where he set up several disease-focused research centers.¹ He has authored over 900 scientific publications, holds more than 130 patents, is frequently cited among top life-science researchers, and is a Fellow of the American Association for the Advancement of Science.¹

On compensation, Reed will receive a $50,000 annual cash retainer as a non-employee director plus $10,000 annually for his committee service.¹ He will also receive an equity award valued at $675,000, split evenly between stock options and restricted stock units under the company's 2026 Stock Plan.¹ The options vest half after one year and the remainder in quarterly installments over the following year, while the RSUs vest in two equal annual installments.¹ Madrigal stated there were no side arrangements tied to his selection and no related-party interests requiring disclosure.¹